Last reviewed · How we verify
Autologous Adipose Cells Therapy
At a glance
| Generic name | Autologous Adipose Cells Therapy |
|---|---|
| Sponsor | CERM INC. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Autologous SVF Therapy for Type 2 Diabetes (NA)
- Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars (PHASE1, PHASE2)
- "An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
- Stromal Vascular Fraction (SVF) for Knee Post-Trauma Osteoarthritis (PTOA) (EARLY_PHASE1)
- Tolerance of Intra-articular Injection Autologous Stromal Vascular Fraction for the Treatment of Rhizarthrosis (PHASE2)
- A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects (PHASE1)
- Safety and Potential Effect of Innovative Treatment by Adjuvant Injection of Stromal Vascular Fraction From Autologous Adipose Tissue of URethral Stenosis With Endoscopic Urethrotomy (PHASE2)
- Treatment of Osteoarthritis of the Hip Joint With Intra-articular Injection of Microfractured Autologous Adipose Tissue Containing Mesenchymal Stromal Cells. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous Adipose Cells Therapy CI brief — competitive landscape report
- Autologous Adipose Cells Therapy updates RSS · CI watch RSS
- CERM INC. portfolio CI